ype B acute aortic dissection (AAD) without fatal complications, such as rupture or vital organ ischemia, is considered to be an indication for medical rather than surgical treatment, as previous investigators have demonstrated that its prognosis is acceptable with medical therapy. [1] [2] [3] However, medical treatment protocols for patients with type B AAD in the acute phase remain unclear. Some patients are complicated by pneumonia, heart failure or delirium associated with complete bed rest and intensive care unit (ICU) stay. Furthermore, these factors may cause refractory hypertension and medical antihypertensive therapy is difficult for these complications with a prolonged admission period. The incidence of early rupture or visceral ischemia is considered to be rare after admission, so we expect that morbid complications would occur more frequently during the days of strict bed rest. The aim of this study was to assess the outcome of our clinical pathway for patients with type B AAD in the acute phase and we also examined the effect of early rehabilitation.
Methods

Patient Population
Between January 1996 and August 2007, 223 patients with type B AAD were admitted during the acute phase (within 2 weeks of onset). Emergency surgical intervention was required in 8 patients (2 with leg ischemia underwent axillo-femoral bypass, 1 underwent intestinal resection because of bowel ischemia, 5 with rupture or impending rupture underwent distal-descending replacement) and 5 patients experienced malperfusion. We omitted those 13 patients and analyzed the other 210 uncomplicated cases of type B AAD. Aortic dissection was classified as type B, according to the Stanford system proposed in 1970, 4 if it did not involve the ascending aorta. 4 Diagnosis was made using computed tomography in all patients.
Medical Therapy and Clinical Pathway
Up to January 2002, We treated patients medically at the time of onset, regardless of the diameter of the dissected aorta and blood patency status of the false lumen. The protocol included ICU admission with arterial pressure monitoring, central venous access for the administration of intravenous antihypertensive medications, and urine output monitoring via a bladder catheter. From January 2002, we initiated a clinical pathway for patients with type B AAD in the acute phase. The study group was subdivided: Conventional therapy group (CG) of 90 (58 males; mean age 64.5± 10.6 years, range 33-83) who were treated by 7 days of bed rest and intravenous antihypertensive agents in the first (Fig 1) : each patient was administered oral medication from the 1 st or 2 nd day after onset and took a short walk from the 3 rd day after onset. For blood pressure control, all patients received an intravenous calcium-channel blocker, nitroglycerine, β-blockers or a combination after admission. In both groups, systolic blood pressure was controlled under 120 mmHg with careful observation of urine output. If urine output fell, blood pressure was controlled to approximately 140 mmHg. Treatment of refractory hypertension requires more than 3 intravenous antihypertensives. All patients received oral calcium-channel blockers and the angiotensinconverting enzyme inhibitor (ACEI), imidapril, or the angiotensin II receptor blocker (ARB), termisaltan, β-blockers, or a combination. Pain in many cases was reduced without requiring an analgesic after blood pressure was controlled. If pain continued, an intravenous non-narcotic analgesic (buprenorphine hydrochloride) or narcotic analgesic (morphine hydrochloride) was administered. When a patient complained of pain, if the drugs were ineffective under controlled blood pressure, then rupture, re-dissection or organ ischemia was confirmed or ruled out by emergency computed tomography. If the maximum diameter of the dissected aorta exceeded 60 mm at the time of onset, early operation was scheduled. All patients underwent contrast computed tomographic scanning at emergency admission, on the 1 st and 7 th days after admission and 1 month later. We measured the maximum diameter of the descending aorta and the diameter of the false lumen at the same level. Patients in the CPG could be moved from the ICU 1-3 days after onset, and could go home 4 weeks after onset. Symptoms such as severe chest or back pain usually disappeared after admission, so patients often forgot their critical condition and during their hospital stay, we had to gradually educate them about the importance of maintaining appropriate levels of blood pressure, oral medication, cessation of smoking, and exercise. In the present study, we compared the initiation of oral medications, diet, and walking, incidence of pneumonia, delirium, and respiratory failure requiring respirator and ICU stay, freedom from emergency operation, early mortality and the diameter of the aorta and false lumen at the time of onset and 1 month later in the CG and CPG. We compared the cost of treatment for patients in both groups without complications in the first week after admission. No patients in this study had neurological complications or retrograde type A AAD.
Statistical Analysis
Analysis was retrospective. Patients were followed until death or until the outpatient clinic. For parametric data, the results are expressed as the mean ± standard deviation and statistically significant differences were determined using Student's t-test. Differences between categorical factors were assessed using χ2 analysis or Fisher's exact test when appropriate; P<0.05 was considered statistically significant. Data analysis was performed using StatView J-5.0 for Windows (Abacus Concepts, Calabasus, CA, USA).
Results
In the CG, 55 patients (61.1%) and 80 patients in the CPG (66.7%) had a thrombosed occlusion of the false lumen at the time of admission; 66 patients (73.3%) in the CG and 96 (80.0%) in the CPG were classified as DeBakey IIIb ( Table 2) .
One patient in the CPG developed paraplegia and acute renal failure and 1 patient in each group underwent emergency axillo-femoral bypass because of leg ischemia. Three patients in the CG died: 1 died of severe bronchial asthma attack after admission, another died from multiple organ fail- ure, and the other died of sepsis after the axillo-femoral bypass. Three patients in the CPG died: 1 died of gut ischemia after admission, 3 days after onset, 1 had an aortic diameter of 65 mm at the time of onset, but refused operation and died of aortic rupture 3 days after the onset, and 1 died of visceral ischemia caused by re-dissection at 7 days after onset ( Table 3) . The time of beginning oral medication and diet was significantly (P<0.001) later in the CG than in the CPG: 5.8± 4.4 and 8.1±5.2 days, and 1.4±1.4 and 2.0±1.0 days, respectively. The length of ICU stay was significantly (P<0.001) longer in the CG (6.1±5.5 days) than in CPG (2.0±2.3 days). The duration of bed rest was also significantly (P<0.001) longer in the CG (11.2±6.3 days) than in the CPG (2.3±1.9 days). The mean modality of intravenous antihypertensive drugs was significantly (P<0.001) more in the C group (1.9± 0.9) than in the CPG (1.5±0.7). The incidence of refractory hypertension was significantly (P<0.001) higher in the CG (26.7%: 24/90) than in the CPG (3.0 %: 4/120). Initiation of walking was significantly (P<0.001) later in the CG (13.3± 6.1 days) than in the CPG (3.7±2.4 days) ( Table 4) . Maximum diameters of the dissected aorta and false lumen at the same level at the time of onset were similar in the CG and CPG: 40.8±9.6 mm and 13.0±8.8 mm, and 37.0±8.0 mm and 12.1±7.2 mm, respectively. The diameters had not enlarged 1 month later and were similar in the CG and CPG: 40.7± 8.8 mm and 11.7±8.5 mm, and 36.2±6.7 mm and 11.6± 7.9 mm, respectively ( Table 5 ). Both the incidence of pneumonia and need for a respirator were significantly higher in the CG (23.3% and 11.1%) than in the CPG (4.2% and 3.3%). The incidence of delirium was significantly (P<0.001) higher in the CG (22.2%) than in the CPG (5.8%). Early mortality at 1 month was similar in both groups (CG: 3.3%; CPG: 2.5%) ( Table 6 ). The operation-free rate and the actuarial survival rate at 1, 5, and 10 years of the patients in the CG were 92.1% and 82.6%, 74.2% and 96.7%, and 89.8% and 73.1%, respectively, and the CPG the operation-free rate and the actuarial survival rate at 1 and 5 years were 93.7% and 83.1%, and 95.7% and 90.9%, respectively (Figs 2A,B) . Surgical intervention was required for 21 patients in the CG (mean follow-up 80.9±38.2 months, 3.5/100 patients-year) and 11 patients in the CPG (mean follow-up 27.3±21.4 months, 4.0/100 patients-year). During the follow-up period, 18 patients in the CG died (mean follow-up 92.2±31.9 months, 2.6/100 patients-year) and 7 in the CPG (mean follow-up 30.8±21.3 months, 2.3/100 patients-year). The median total cost of medical treatment for patients without complication in the first week after admission was significantly (P<0.001) higher in the CG (US$800) than in the CPG (US$400).
Discussion
The mortality rate of patients undergoing surgical intervention for type B AAD is still high. 5 Gysi et al reported that the 30-day mortality rate of type B AAD was lower and that death usually occurred later, as did aneurysmas in the descending aorta, 6 but in a recent report, the mortality of a subgroup patients with type B AAD treated with endovascular stenting was still significant at 10%, with an incidence of paraplegia of 2-3%. 7 Early outcomes with endovascular stenting do not appear better than medical treatment for type B AAD. The mortality rate for medical treatment is reported to be better than that for surgical intervention during the acute phase, [8] [9] [10] so it has been generally advocated that patients with type B AAD without complications (such as rupture or visceral ischemia) should be treated with hypotensive drugs at the time of onset, and surgical treatment should be carried out only if the aortic diameter enlarges during the follow-up period. 11 However, the optimal medical Abbreviations see in Table 1 . Tables 1,3 . treatment protocol for patients with type B AAD remains unclear and controversial. For example, the duration of bed rest, when to begin diet and oral medications, initiation of walking after onset, etc. Of course, bed rest is necessary and important for antihypertensive therapy, but on the other hand, bed rest is a risk factor of deep vein thrombosis, pulmonary thromboembolism, pneumonia, and mental stress. Therefore, aggressive pulmonary therapy and deep venous thrombosis prophylaxis using low-molecular-weight heparins or sequential compression stockings are used when lowmolecular-weight heparins are contraindicated. 12 Our clinical pathway protocol for type B AAD does not use deep venous thrombosis prophylaxis with low-molecular-weight heparins or sequential compression stockings, but in the present series, none of the patients had deep venous thrombosis. We think that a short duration of bed rest is an effective prophylaxis for deep venous thrombosis. Similarly, some patients become complicated with pneumonia and/or delirium because of bed rest and ICU stay, and medical antihypertensive therapy is not enough to prevent these complications or a longer hospital stay. In patients with type B AAD, we think that it is important to reduce the mental and physical stress and to prevent the onset of delirium and pneumonia with appropriate medical treatment. In the present CPG, the incidences of pneumonia, delirium and need for a respirator were significantly lower than in the CG, the complications related to prolonged bed rest must and can be prevented. Although some patients still had complications and had to be kept in bed slightly longer than 2 days, in the present study, even though the initial strategy differed, the difference in the duration of bed rest meant a better outcome in the CPG. We usually transfer patients with type B AAD from the ICU to the surgical ward 1-3 days after onset and in the surgical ward, gentle exercise as early as possible is recommended. In both groups in the present study, the maximum diameter of the dissected aorta at the time of onset was similar and had not enlarged 1 month later. Early mortality were similar in both groups. Our clinical pathway for patients with type B AAD reduced the incidence of critical complications in the acute phase, but did not deteriorate the operation-free rate or actuarial survival rate in the chronic phase. Iguchi and Takabayashi reported that medical treatment was indicated for all patients with uncomplicated type B dissection if the diameter of the dissected aorta was less than 50 mm and substantial enlargement of the dissected aorta was not observed after a short interval. 5 Sakakura et al reported a maximum aortic diameter >60 mm as the independent predictor of in-hospital events in type B AAD. 13 Calcium antagonists are clearly effective in reducing elevated blood pressure with minimal to modest adverse effect profiles, and were therefore used extensively as the first-line agent for treating hypertension in patients with type B AAD. Long-term treatment with β-blockers reduced the progression of aortic dilatation, and freedom from subsequent aortic operation was 80% with β-blockers and 47% with another hypotensive drug; 14 however, we hesitated to use β-blockers for all patients because some were complicated by bronchial asthma, heart failure, or bradycardia. Therefore, we used β-blockers for patients with tachycardia, and/or a patent false lumen. Telmisartan, an ARB, hasa great effect on blood pressure during the early morning in patients with hypertension. Furthermore, the effects of this ARB have been evaluated on a day when the dose was missed, thereby evaluating the effects from 24 to 48 h after dosing. 15 The ACEI, imidapril, which is in a class of antihypertensive agents that induces coughing, is an independent factor in reducing the risk of pneumonia among elderly inpatients. 16 We think there are 2 important points to medical treatment for type B AAD: lowering blood pressure as soon as possible to relieve pain, and relieving mental and physical stress to lower blood pressure. The outcome of medical treatment in our clinical pathway was acceptable and we recommend it for every case of type B AAD without complications on admission.
In conclusion, medical treatment for type B AAD is associated with acceptable outcomes, especially in uncomplicated cases. Our clinical pathway for patients with type B AAD reduced the incidence of critical complications such as pneumonia, delirium, or refractory hypertension. Furthermore, our new strategy for type B AAD shortens the hospital stay and reduces the cost of intravenous medications and ICU stay. It was safe and effective for type B AAD in the acute phase. 
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Study Limitations First, the number of patients was relatively small and second, this study was performed at a single center. We continue this study, based on these results, and will increase the number of the cases.
